Dexcom’s Jake Leach Named Chair of AdvaMed’s Diabetes Sector

WASHINGTON-AdvaMed, the Medtech Association, today announced that Jacob "Jake" Leach, President and Chief Executive Officer at Dexcom, will serve as the next chair of the AdvaMed Diabetes Sector, succeeding Chris Scoggins, Executive Vice President of Diabetes Care at Abbott. The AdvaMed Diabetes Sector represents the world's leading companies producing technology across the spectrum of diabetes care.

"Jake brings decades of experience advancing patient-centered diabetes care and driving innovation across the medtech industry," said Scott Whitaker, AdvaMed President and CEO. "The AdvaMed Diabetes Sector plays a critical role in advocating for policies that expand access to diabetes technologies, improve patient outcomes, and support equitable care for all patients. Thank you, Jake, for your willingness to lead in this important role."

Whitaker also expressed gratitude to Scoggins for his leadership. "Chris led the AdvaMed Diabetes Sector with a clear focus on the patients and families who depend on these technologies every day," Whitakersaid. "At a time of rapid innovation and important policy conversations around access and affordability, his leadership helped strengthen our voice and advance solutions that empower people with diabetes to live healthier, fuller lives."

Eric Benjamin, Executive Vice President and Chief Operating Officer at Insulet, will serve as the sector's vice chair.

Leach has spent nearly 22 years at Dexcom, helping grow the company from 30 employees to more than 10,000 worldwide. Under his leadership, Dexcom has expanded access to diabetes management tools and partnered with consumer tech companies and public figures to raise awareness of diabetes care.

"It is an honor to serve as chair of the AdvaMed Diabetes Sector," Leachsaid. "I look forward to collaborating with the diabetes sector member companies to advance innovation in diabetes care, ensure people can access life-changing technologies, and continue advocating for policies that prioritize health outcomes."

The AdvaMed Diabetes Sector advocates for policies that support the 40 million Americans living with diabetes and the 115 million Americans living with prediabetes by developing innovative medtech that empowers patients with real-time data, alerts, and insights to manage their health and prevent serious complications through early detection and intervention.

AdvaMed diabetes sector member companies cover the range of care across the diabetes ecosystem, including technologies that help prevent, diagnose, treat, monitor, and manage the complications of diabetes. These companies include:Abbott, Ascensia Diabetes Care, Baxter International Inc., Boston Scientific Corporation, Bruin Biometrics, Cardinal Health, CeQur, Dexcom, Digital Diagnostics, Eli Lilly and Company, embecta, Endogenex, Glooko, Humacyte, Inc., Ideal Medical Technologies, Indigo Diabetes NV, Insulet, Johnson & Johnson MedTech, Medtronic, Morphic Medical, Novo Nordisk, Philips, Phoenix NeuroStim Therapeutics, Podimetrics, Roche Diagnostics, Senseonics, Siemens Healthineers, Siren Care, Inc., Tandem Diabetes Care, Inc., and Verily Life Sciences.

###

Share this article:

• Share this page on Twitter
• Share this page on Facebook
• Share this page on LinkedIn
• Email a link to this page

Related Reading

Blog / Diagnostics / Digital Health / Government & Legislative Affairs / Health Access

Heart Month: Why Sleep Apnea Belongs at the Center of Cardiovascular Care

February 13, 2026

February is American Heart Month-a time to spotlight cardiovascular disease and highlight innovations that can improve patient outcomes. For the medtech community, it's an opportunity to address persistent gaps in care through technology, data, collaboration, and policy advancement. Despite progress in treating heart conditions, sleep disorders-especially sleep apnea-remain a significant and underrecognized contributor to poor cardiovascular outcomes.1 Tackling this issue requires clinical awareness and supportive policies for timely diagnosis, coverage, and care beyond traditional settings.

News / Diagnostics / Digital Health / Medical Imaging / Regulatory Affairs

AdvaMed Receives RAPS Accreditation for Medical Device Submissions Workshop Series (February 2026 in Washington, D.C.)

February 4, 2026

WASHINGTON, D.C.-AdvaMed, the world's largest trade association representing medical technology innovators, announced that its Medical Device Submissions Workshop Series (February 23-27 in Washington, D.C.) has been officially approved for RAC recertification credits by the Regulatory Affairs Professionals Society (RAPS).

Blog / Artificial Intelligence (AI) / Diagnostics / Digital Health / Health Access

The Insight Series: AI & Digital Health

January 30, 2026

AdvaMed Digital Health Tech division member companies include world leaders in developing AI-enabled solutions to improve health and care, from diagnosis to treatment, clinical decision support, and wearables to wellness. "The Insight Series: AI & Digital Health" will feature company experts, answering pressing questions to inform policymakers and the public about how AI and digital health are transforming care and delivery. Our inaugural entry is a conversation between Melissa Cha of Amazon and Taha Kass-Hout of GE HealthCare.

Blog / Diagnostics / Digital Health / Regulatory Affairs / Standards

Honoring Janet E. Trunzo: A Legacy That Shaped Modern Medtech Regulation

January 29, 2026

After 30 years at AdvaMed, Janet E. Trunzo, Senior Advisor to the President and Senior Executive Vice President of Technology and Regulatory Affairs, will retire on January 31, 2026. Her tenure has fundamentally shaped how medical devices are regulated in the United States and globally, establishing frameworks and standards that continue to govern the field today.

Blog / Artificial Intelligence (AI) / Coverage & Payment / Diagnostics / Digital Health / Government & Legislative Affairs / Health Access / Medical Imaging

Why the Health Tech Investment Act Matters: Peter Weems Breaks Down What This Means for Patients

January 26, 2026

In a new video developed in partnership with Patients Rising, AdvaMed's Peter Weems, Vice President of Imaging Government Affairs and Policy Strategy, explains why the Health Tech Investment Act is critical to expanding patient access to FDA-authorized AI-enabled medical devices.

News / Artificial Intelligence (AI) / Coverage & Payment / Diagnostics / Digital Health / Government & Legislative Affairs / Medical Imaging / Regulatory Affairs

Medical Imaging Division Announces Rich Fabian as New Board Chair

January 16, 2026

WASHINGTON, D.C.-AdvaMed, the Medtech Association, today announced that Rich Fabian, president and CEO of FUJIFILM Sonosite, will serve as the chair of the Medical Imaging division's board of directors. He will succeed David Pacitti, CEO of Avanos Medical and former president and head of the Americas at Siemens Healthineers, the inaugural division board chair.

News / Artificial Intelligence (AI) / Coverage & Payment / Diagnostics / Digital Health / Government & Legislative Affairs / Orthopedic / Regulatory Affairs

Robert Cohen of Stryker Named Chair of AdvaMed's Digital Health Tech Division Board of Directors

January 5, 2026

WASHINGTON, D.C.-AdvaMed, the Medtech Association, today announced that Robert Cohen, vice president, innovation and technology, orthopaedic group at Stryker, will be the next chair of the AdvaMed Digital Health Tech Board of Directors. He succeeds Dr. Taha Kass-Hout, global chief science and technology officer at GE HealthCare, who served as the inaugural chair of the board overseeing the then-newly created division.

News / Artificial Intelligence (AI) / Coverage & Payment / Diagnostics / Digital Health / Government & Legislative Affairs / Medical Imaging / Orthopedic / Regulatory Affairs / Small Business

Mick Farrell, Chairman and CEO of Resmed, Named Chair of AdvaMed Board of Directors

December 11, 2025

WASHINGTON, D.C.-AdvaMed, the Medtech Association, today announced Michael "Mick" Farrell, chairman and CEO of Resmed Inc. (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, will be the next chair of the AdvaMed Board of Directors. Farrell will serve a two-year term beginning in January 2026.